Roche heirs bid goodbye to ‘unsustainable’ philanthropy
Andre Hoffmann
Keystone / Georgios Kefalas
The heirs of Switzerland’s pharmaceutical company Roche are ending an era as philanthropic donors for major nature conservation projects, the NZZ am Sonntag reported.
This content was published on
2 minutes
Русский
ru
Концерн Roche прощается с «нерентабельной» филантропией
Their Mava Foundation, established 25 years ago, will shut down next year. “The traditional form of philanthropy has failed,” Roche Vice Chairman Andre Hoffmann told the German-language weekly in an interview published on Sunday.
Transferring money because you have a guilty conscience doesn’t do any good, the 63-year-old foundation president and economist explained.
“You may feel good about it yourself, but it doesn’t solve the problems,” he said. “Projects that exist only as long as we pay and stop when we withdraw are misguided.”
At last count, the Mava Foundation was involved in 180 projects with 120 partners. Many managed to continue and survive on their own, according to Hoffmann, spokesman for the Roche shareholder pool.
The foundation’s closure has been in the works for years.
Founded in 1994
The foundation, based in the town of Gland, canton Vaud, had been established in 1994. Launched by Hoffmann’s father, Luc, its original aim was to protect unique landscapes such as the Camargue.
Hoffmann told the newspaper he and his children would continue to support projects provided that they are based on a business model that ensured survival.
“The success of a project should not depend on the donor,” he stressed.
Hoffmann, who is involved in more than a dozen charitable activities, also called for greater accountability from companies when consumption of their products causes harm.
Food manufacturers, for example, should have to answer for health damage caused by excessive sugar content in their products, he said.
Greenwashing
He also criticised the way many companies still develop products without paying attention to their ecological footprint. It is only later that something is donated.
These companies, he argues, are guilty of greenwashing. “It’s not how you spend the money that matters, it’s how you do it,” he said.
Hoffmann believes the financial industry has the highest potential to make an impact because “it determines where the capital of pension funds and other investors goes”.
Popular Stories
More
Swiss Abroad
The citizenship obstacle course facing spouses of Swiss Abroad
This content was published on
The Ethos Foundation recommends that shareholders vote against all compensation-related items at the Annual General Meeting on March 7.
Top Swiss firms close to reaching gender quota in boards
This content was published on
The proportion of women on the boards of directors of the fifty largest listed companies in Switzerland currently stands at 28%.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Eight Swiss in Bloomberg billionaire ‘rich list’
This content was published on
In the latest version of the Bloomberg Billionaires Index, eight Swiss or Swiss-resident names figure among the 500 richest people in the world.
Swiss pharma industry fights lower drug prices in the US
This content was published on
A proposed US law aims to lower prescription drug prices. But Big Pharma is pulling out all the stops to lobby against it.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.